Abstract
Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Current Cancer Drug Targets
Title:Current Drug Targets for Thymic Neoplasms
Volume: 15 Issue: 7
Author(s): Xiao-Ling Xu and Wei-Min Mao
Affiliation:
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Abstract: Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Export Options
About this article
Cite this article as:
Xu Xiao-Ling and Mao Wei-Min, Current Drug Targets for Thymic Neoplasms, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150616124155
DOI https://dx.doi.org/10.2174/1568009615666150616124155 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging In vitro Propagation of Cichorium intybus L. and Quantification of Enhanced Secondary Metabolite (Esculin)
Recent Patents on Biotechnology The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
Anti-Cancer Agents in Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals